Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

(2015) A. Kavanaugh et al.   JOURNAL OF RHEUMATOLOGY

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

(2014) P.H. Schafer et al.   CELLULAR SIGNALLING

GRAPPA Treatment Recommendations: An Update from the GRAPPA 2013 Annual Meeting

(2014) L. C. Coates et al.   JOURNAL OF RHEUMATOLOGY

Psoriatic arthritis: current therapy and future approaches

(2014) D. Huynh et al.   RHEUMATOLOGY

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

(2013) Vibeke Strand et al.   Health and Quality of Life Outcomes

Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

(2012) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

(2012) Peter Schafer   BIOCHEMICAL PHARMACOLOGY

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

(2012) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

(2012) Kim Papp et al.   LANCET

Psoriatic arthritis: update on pathophysiology, assessment and management

(2011) P. J. Mease   ANNALS OF THE RHEUMATIC DISEASES

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

(2011) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice

(2010) Jean-Hilaire Saurat et al.   DERMATOLOGY

Novel mechanism of signaling by CD28

(2010) Elisa Bjørgo et al.   IMMUNOLOGY LETTERS

Predictors of response to intra-articular steroid injection in psoriatic arthritis

(2010) L. Eder et al.   RHEUMATOLOGY

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

(2010) Fiona E McCann et al.   ARTHRITIS RESEARCH & THERAPY

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

(2010) Georg Schett et al.   Therapeutic Advances in Musculoskeletal Disease

Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

(2009) J R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment

(2009) M. Brenner et al.   BRITISH JOURNAL OF DERMATOLOGY

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

(2009) PH Schafer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

(2009) Zehra Kaymakcalan et al.   CLINICAL IMMUNOLOGY

CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease

(2009) J.N. Gordon et al.   Journal of Crohns & Colitis

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

(2009) Hon-Wah Man et al.   JOURNAL OF MEDICINAL CHEMISTRY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2009) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION

A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis

(2007) V Ravindran et al.   ANNALS OF THE RHEUMATIC DISEASES